A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA)

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab compared with a matching placebo in combination with standard of care in hospitalized patients with severe COVID-19 pneumonia.

Imperial PI Dr Nichola Cooper
Trial Sponsor Hoffmann-La Roche
Study type Interventional
Study status Closed to recruitment

ClinicalTrials.Gov record

Participants recruited to date: